Topical pimecrolimus in the treatment of vitiligo.
Although the treatment of vitiligo has improved during the last decade, therapy is still not satisfactory for many patients. Recently topical calcineurin inhibitors were introduced in the treatment of atopic dermatitis. Considering the autoimmune hypothesis of vitiligo pathogenesis, the use of these topical calcineurin inhibitors seems reasonable. Most clinical vitiligo trials have been performed with tacrolimus and show beneficial effects. Concerning the value of pimecrolimus in the treatment of vitiligo only few data are available. Therefore we performed an open pilot study in 26 patients to evaluate the efficacy and safety of 1% pimecrolimus in the treatment of vitiliginous lesions in the head and neck region. In 13 of 26 (50%) evaluated target lesions, repigmentation was noted after a 6 month treatment period with a median percentage of repigmentation of 72.9% (interquartile range: 30.5-98.3%). Duration of vitiligo and total affected body surface area tended to be inversely correlated with the success rate of treatment. Side effects were mainly limited to a burning sensation at the application site. Despite the promising results of topical immunomodulators in the treatment of vitiligo, prudence is in order, as long-term follow up studies are still lacking.
Boone
Barbara
B
Department of Dermatology, University Hospital of Ghent, De Pintelaan 185, 9000 Ghent, Belgium. barbara.boone@ugent.be
Ongenae
Katia
K
Van Geel
Nanny
N
Vernijns
Sander
S
De Keyser
Stefanie
S
Naeyaert
Jean-Marie
JM
D000287:Administration, Topical; D000328:Adult; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014820:Vitiligo / Q000188:drug therapy*
D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus